Are Curcuminoids Effective C‐Reactive Protein‐Lowering Agents in Clinical Practice? Evidence from a Meta‐Analysis
Background: Inflammation plays a pivotal role in the pathogenesis of atherosclerosis and cardiovascular disease (CVD). In this context, C‐reactive protein (CRP) has been identified as a strong predictor and independent risk factor of CVD. Curcuminoids are multifunctional natural product with promisi...
Gespeichert in:
| Veröffentlicht in: | Phytotherapy research 2014-05, Vol.28 (5), p.633-642 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 642 |
|---|---|
| container_issue | 5 |
| container_start_page | 633 |
| container_title | Phytotherapy research |
| container_volume | 28 |
| creator | Sahebkar, Amirhossein |
| description | Background: Inflammation plays a pivotal role in the pathogenesis of atherosclerosis and cardiovascular disease (CVD). In this context, C‐reactive protein (CRP) has been identified as a strong predictor and independent risk factor of CVD. Curcuminoids are multifunctional natural product with promising cardioprotective and anti‐inflammatory properties. Curcuminoids have been suggested to lower circulating levels of CRP, but clinical findings have not been consistent. Objectives: To pool the published results of clinical trials on the impact of supplementation with curcuminoids on circulating levels of CRP. Methods: PubMed/MEDLINE and SCOPUS databases were searched for clinical trials reporting circulating CRP changes in individuals receiving curcuminoids. Effect sizes with 95% confidence intervals (CI) were calculated using a random‐effects model. Inter‐study heterogeneity was assessed using Cochran's Q and I² tests. Sensitivity analyses were conducted using leave‐one‐out method. Results: Six trials comprising 172 subjects in the curcuminoids group and 170 subjects in the placebo group fulfilled the eligibility criteria and included in the meta‐analysis. Compared with placebo, supplementation with curcuminoids was associated with a significant reduction in circulating CRP levels (weighed mean difference: −6.44 mg/L; 95% CI: −10.77 – −2.11; p = 0.004). This significant effect was maintained in subgroups of trials that used bioavailability‐improved preparations of curcuminoids and had supplementation duration of ≥4 weeks, but not in the subgroups without these characteristics. Conclusions: Supplementation with curcuminoids may reduce circulating CRP levels. This effect appears to depend on the bioavailability of curcuminoids preparations and also duration of supplementation. Future well‐designed and long‐term trials are warranted to verify this effect of curcuminoids. Copyright © 2013 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/ptr.5045 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1518620308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3281151761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3785-1df388c22971f3d37d92d6b8e678aa039aa8f148c63b3d7a2b583aee85264d883</originalsourceid><addsrcrecordid>eNpd0d1u0zAUB3ALgVgZSDwBROKGmwx_xIl9hbqqG4huVGMTiBvLtU8qj8QpdrKudzwCz8iT4NAxJK6OfPw71pH_CD0n-IhgTN9s-nDEccEfoAnBUuaEV-whmmDJSV4Q8eUAPYnxGmMsKS4eowPKJKWU8QnaTgNksyGYoXW-czZm87oG07ub1P714-cF6P1hGboenE-tRbeF4Pw6m67B9zFzPps1zjujm6RGbuBtNr9xFryBrA5dm-nsDHqdhqdeN7vo4lP0qNZNhGd39RBdncwvZ-_yxcfT97PpIjesEjwntmZCGEplRWpmWWUlteVKQFkJrTGTWouaFMKUbMVspemKC6YBBKdlYYVgh-j1_t1N6L4PEHvVumigabSHboiKcCJKihke6av_6HU3hLTvH1VJyQsuk3pxp4ZVC1Ztgmt12Km_X5pAvgdb18Du_p5gNUalUlRqjEotLy_G-s-72MPtvdfhmyorVnH1-fxUfZUflqU4P1PHyb_c-1p3Sq-Di-rqE8WkSPGmJdPMb2VcoEU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1517995459</pqid></control><display><type>article</type><title>Are Curcuminoids Effective C‐Reactive Protein‐Lowering Agents in Clinical Practice? Evidence from a Meta‐Analysis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Sahebkar, Amirhossein</creator><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><description>Background: Inflammation plays a pivotal role in the pathogenesis of atherosclerosis and cardiovascular disease (CVD). In this context, C‐reactive protein (CRP) has been identified as a strong predictor and independent risk factor of CVD. Curcuminoids are multifunctional natural product with promising cardioprotective and anti‐inflammatory properties. Curcuminoids have been suggested to lower circulating levels of CRP, but clinical findings have not been consistent. Objectives: To pool the published results of clinical trials on the impact of supplementation with curcuminoids on circulating levels of CRP. Methods: PubMed/MEDLINE and SCOPUS databases were searched for clinical trials reporting circulating CRP changes in individuals receiving curcuminoids. Effect sizes with 95% confidence intervals (CI) were calculated using a random‐effects model. Inter‐study heterogeneity was assessed using Cochran's Q and I² tests. Sensitivity analyses were conducted using leave‐one‐out method. Results: Six trials comprising 172 subjects in the curcuminoids group and 170 subjects in the placebo group fulfilled the eligibility criteria and included in the meta‐analysis. Compared with placebo, supplementation with curcuminoids was associated with a significant reduction in circulating CRP levels (weighed mean difference: −6.44 mg/L; 95% CI: −10.77 – −2.11; p = 0.004). This significant effect was maintained in subgroups of trials that used bioavailability‐improved preparations of curcuminoids and had supplementation duration of ≥4 weeks, but not in the subgroups without these characteristics. Conclusions: Supplementation with curcuminoids may reduce circulating CRP levels. This effect appears to depend on the bioavailability of curcuminoids preparations and also duration of supplementation. Future well‐designed and long‐term trials are warranted to verify this effect of curcuminoids. Copyright © 2013 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0951-418X</identifier><identifier>EISSN: 1099-1573</identifier><identifier>DOI: 10.1002/ptr.5045</identifier><identifier>PMID: 23922235</identifier><identifier>CODEN: PHYREH</identifier><language>eng</language><publisher>England: J. Wiley</publisher><subject>anti-inflammatory ; Anti-Inflammatory Agents - pharmacology ; atherosclerosis ; Bioavailability ; C-Reactive Protein - metabolism ; Cardiovascular Diseases - prevention & control ; Clinical trials ; Clinical Trials as Topic ; confidence interval ; Confidence intervals ; coronary heart disease ; Curcuma longa L ; curcumin ; Curcumin - analogs & derivatives ; Curcumin - pharmacology ; Dietary Supplements ; Drug therapy ; Humans ; inflammation ; pathogenesis ; risk factors ; turmeric</subject><ispartof>Phytotherapy research, 2014-05, Vol.28 (5), p.633-642</ispartof><rights>Copyright © 2013 John Wiley & Sons, Ltd.</rights><rights>Copyright © 2014 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3785-1df388c22971f3d37d92d6b8e678aa039aa8f148c63b3d7a2b583aee85264d883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fptr.5045$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fptr.5045$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23922235$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><title>Are Curcuminoids Effective C‐Reactive Protein‐Lowering Agents in Clinical Practice? Evidence from a Meta‐Analysis</title><title>Phytotherapy research</title><addtitle>Phytother. Res</addtitle><description>Background: Inflammation plays a pivotal role in the pathogenesis of atherosclerosis and cardiovascular disease (CVD). In this context, C‐reactive protein (CRP) has been identified as a strong predictor and independent risk factor of CVD. Curcuminoids are multifunctional natural product with promising cardioprotective and anti‐inflammatory properties. Curcuminoids have been suggested to lower circulating levels of CRP, but clinical findings have not been consistent. Objectives: To pool the published results of clinical trials on the impact of supplementation with curcuminoids on circulating levels of CRP. Methods: PubMed/MEDLINE and SCOPUS databases were searched for clinical trials reporting circulating CRP changes in individuals receiving curcuminoids. Effect sizes with 95% confidence intervals (CI) were calculated using a random‐effects model. Inter‐study heterogeneity was assessed using Cochran's Q and I² tests. Sensitivity analyses were conducted using leave‐one‐out method. Results: Six trials comprising 172 subjects in the curcuminoids group and 170 subjects in the placebo group fulfilled the eligibility criteria and included in the meta‐analysis. Compared with placebo, supplementation with curcuminoids was associated with a significant reduction in circulating CRP levels (weighed mean difference: −6.44 mg/L; 95% CI: −10.77 – −2.11; p = 0.004). This significant effect was maintained in subgroups of trials that used bioavailability‐improved preparations of curcuminoids and had supplementation duration of ≥4 weeks, but not in the subgroups without these characteristics. Conclusions: Supplementation with curcuminoids may reduce circulating CRP levels. This effect appears to depend on the bioavailability of curcuminoids preparations and also duration of supplementation. Future well‐designed and long‐term trials are warranted to verify this effect of curcuminoids. Copyright © 2013 John Wiley & Sons, Ltd.</description><subject>anti-inflammatory</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>atherosclerosis</subject><subject>Bioavailability</subject><subject>C-Reactive Protein - metabolism</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>confidence interval</subject><subject>Confidence intervals</subject><subject>coronary heart disease</subject><subject>Curcuma longa L</subject><subject>curcumin</subject><subject>Curcumin - analogs & derivatives</subject><subject>Curcumin - pharmacology</subject><subject>Dietary Supplements</subject><subject>Drug therapy</subject><subject>Humans</subject><subject>inflammation</subject><subject>pathogenesis</subject><subject>risk factors</subject><subject>turmeric</subject><issn>0951-418X</issn><issn>1099-1573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0d1u0zAUB3ALgVgZSDwBROKGmwx_xIl9hbqqG4huVGMTiBvLtU8qj8QpdrKudzwCz8iT4NAxJK6OfPw71pH_CD0n-IhgTN9s-nDEccEfoAnBUuaEV-whmmDJSV4Q8eUAPYnxGmMsKS4eowPKJKWU8QnaTgNksyGYoXW-czZm87oG07ub1P714-cF6P1hGboenE-tRbeF4Pw6m67B9zFzPps1zjujm6RGbuBtNr9xFryBrA5dm-nsDHqdhqdeN7vo4lP0qNZNhGd39RBdncwvZ-_yxcfT97PpIjesEjwntmZCGEplRWpmWWUlteVKQFkJrTGTWouaFMKUbMVspemKC6YBBKdlYYVgh-j1_t1N6L4PEHvVumigabSHboiKcCJKihke6av_6HU3hLTvH1VJyQsuk3pxp4ZVC1Ztgmt12Km_X5pAvgdb18Du_p5gNUalUlRqjEotLy_G-s-72MPtvdfhmyorVnH1-fxUfZUflqU4P1PHyb_c-1p3Sq-Di-rqE8WkSPGmJdPMb2VcoEU</recordid><startdate>201405</startdate><enddate>201405</enddate><creator>Sahebkar, Amirhossein</creator><general>J. Wiley</general><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>FBQ</scope><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201405</creationdate><title>Are Curcuminoids Effective C‐Reactive Protein‐Lowering Agents in Clinical Practice? Evidence from a Meta‐Analysis</title><author>Sahebkar, Amirhossein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3785-1df388c22971f3d37d92d6b8e678aa039aa8f148c63b3d7a2b583aee85264d883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>anti-inflammatory</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>atherosclerosis</topic><topic>Bioavailability</topic><topic>C-Reactive Protein - metabolism</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>confidence interval</topic><topic>Confidence intervals</topic><topic>coronary heart disease</topic><topic>Curcuma longa L</topic><topic>curcumin</topic><topic>Curcumin - analogs & derivatives</topic><topic>Curcumin - pharmacology</topic><topic>Dietary Supplements</topic><topic>Drug therapy</topic><topic>Humans</topic><topic>inflammation</topic><topic>pathogenesis</topic><topic>risk factors</topic><topic>turmeric</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><collection>AGRIS</collection><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Phytotherapy research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sahebkar, Amirhossein</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are Curcuminoids Effective C‐Reactive Protein‐Lowering Agents in Clinical Practice? Evidence from a Meta‐Analysis</atitle><jtitle>Phytotherapy research</jtitle><addtitle>Phytother. Res</addtitle><date>2014-05</date><risdate>2014</risdate><volume>28</volume><issue>5</issue><spage>633</spage><epage>642</epage><pages>633-642</pages><issn>0951-418X</issn><eissn>1099-1573</eissn><coden>PHYREH</coden><abstract>Background: Inflammation plays a pivotal role in the pathogenesis of atherosclerosis and cardiovascular disease (CVD). In this context, C‐reactive protein (CRP) has been identified as a strong predictor and independent risk factor of CVD. Curcuminoids are multifunctional natural product with promising cardioprotective and anti‐inflammatory properties. Curcuminoids have been suggested to lower circulating levels of CRP, but clinical findings have not been consistent. Objectives: To pool the published results of clinical trials on the impact of supplementation with curcuminoids on circulating levels of CRP. Methods: PubMed/MEDLINE and SCOPUS databases were searched for clinical trials reporting circulating CRP changes in individuals receiving curcuminoids. Effect sizes with 95% confidence intervals (CI) were calculated using a random‐effects model. Inter‐study heterogeneity was assessed using Cochran's Q and I² tests. Sensitivity analyses were conducted using leave‐one‐out method. Results: Six trials comprising 172 subjects in the curcuminoids group and 170 subjects in the placebo group fulfilled the eligibility criteria and included in the meta‐analysis. Compared with placebo, supplementation with curcuminoids was associated with a significant reduction in circulating CRP levels (weighed mean difference: −6.44 mg/L; 95% CI: −10.77 – −2.11; p = 0.004). This significant effect was maintained in subgroups of trials that used bioavailability‐improved preparations of curcuminoids and had supplementation duration of ≥4 weeks, but not in the subgroups without these characteristics. Conclusions: Supplementation with curcuminoids may reduce circulating CRP levels. This effect appears to depend on the bioavailability of curcuminoids preparations and also duration of supplementation. Future well‐designed and long‐term trials are warranted to verify this effect of curcuminoids. Copyright © 2013 John Wiley & Sons, Ltd.</abstract><cop>England</cop><pub>J. Wiley</pub><pmid>23922235</pmid><doi>10.1002/ptr.5045</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0951-418X |
| ispartof | Phytotherapy research, 2014-05, Vol.28 (5), p.633-642 |
| issn | 0951-418X 1099-1573 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1518620308 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | anti-inflammatory Anti-Inflammatory Agents - pharmacology atherosclerosis Bioavailability C-Reactive Protein - metabolism Cardiovascular Diseases - prevention & control Clinical trials Clinical Trials as Topic confidence interval Confidence intervals coronary heart disease Curcuma longa L curcumin Curcumin - analogs & derivatives Curcumin - pharmacology Dietary Supplements Drug therapy Humans inflammation pathogenesis risk factors turmeric |
| title | Are Curcuminoids Effective C‐Reactive Protein‐Lowering Agents in Clinical Practice? Evidence from a Meta‐Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T22%3A37%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20Curcuminoids%20Effective%20C%E2%80%90Reactive%20Protein%E2%80%90Lowering%20Agents%20in%20Clinical%20Practice?%20Evidence%20from%20a%20Meta%E2%80%90Analysis&rft.jtitle=Phytotherapy%20research&rft.au=Sahebkar,%20Amirhossein&rft.date=2014-05&rft.volume=28&rft.issue=5&rft.spage=633&rft.epage=642&rft.pages=633-642&rft.issn=0951-418X&rft.eissn=1099-1573&rft.coden=PHYREH&rft_id=info:doi/10.1002/ptr.5045&rft_dat=%3Cproquest_pubme%3E3281151761%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1517995459&rft_id=info:pmid/23922235&rfr_iscdi=true |